Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts. more
Time Frame | APGE | Sector | S&P500 |
---|---|---|---|
1-Week Return | 6.35% | -1.95% | 0.69% |
1-Month Return | -18.84% | -3.36% | 1.53% |
3-Month Return | 3.28% | -6.93% | 11.27% |
6-Month Return | 11.78% | -1.83% | 13.49% |
1-Year Return | 135.46% | 8.53% | 31.62% |
3-Year Return | 188.65% | 7.58% | 30.33% |
Dec '22 | Dec '23 | |||||
---|---|---|---|---|---|---|
Total Revenue | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |||
Cost of Revenue | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |||
Gross Profit | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |||
Gross Margin | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |||
Operating Expenses | 30.73M | 93.00M | [{"date":"2022-12-31","value":33.04,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |||
Operating Income | (30.73M) | (93.00M) | [{"date":"2022-12-31","value":-3072700000,"profit":false},{"date":"2023-12-31","value":-9300300000,"profit":false}] | |||
Total Non-Operating Income/Expense | (18.12M) | 18.04M | [{"date":"2022-12-31","value":-100.44,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] | |||
Pre-Tax Income | (39.78M) | (83.98M) | [{"date":"2022-12-31","value":-3978500000,"profit":false},{"date":"2023-12-31","value":-8398500000,"profit":false}] | |||
Income Taxes | (33.52K) | (93.00K) | [{"date":"2022-12-31","value":-3352000,"profit":false},{"date":"2023-12-31","value":-9300300,"profit":false}] | |||
Income After Taxes | (39.75M) | (83.89M) | [{"date":"2022-12-31","value":-3975148000,"profit":false},{"date":"2023-12-31","value":-8389199700,"profit":false}] | |||
Income From Continuous Operations | (39.78M) | (83.98M) | [{"date":"2022-12-31","value":-3978500000,"profit":false},{"date":"2023-12-31","value":-8398500000,"profit":false}] | |||
Income From Discontinued Operations | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |||
Net Income | (39.78M) | (83.98M) | [{"date":"2022-12-31","value":-3978500000,"profit":false},{"date":"2023-12-31","value":-8398500000,"profit":false}] | |||
EPS (Diluted) | - | (6.99) | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-699,"profit":false}] | |||
These ratios help you determine the liquidity of the company. Higher is better.
APGE | |
---|---|
Cash Ratio | 16.13 |
Current Ratio | 16.39 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
APGE | |
---|---|
ROA (LTM) | -18.52% |
ROE (LTM) | -25.65% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
APGE | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.05 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.95 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
APGE | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 3.87 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Apogee Therapeutics, Inc. Common Stock (APGE) share price today is $49.07
Yes, Indians can buy shares of Apogee Therapeutics, Inc. Common Stock (APGE) on Vested. To buy Apogee Therapeutics, Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in APGE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Apogee Therapeutics, Inc. Common Stock (APGE) via the Vested app. You can start investing in Apogee Therapeutics, Inc. Common Stock (APGE) with a minimum investment of $1.
You can invest in shares of Apogee Therapeutics, Inc. Common Stock (APGE) via Vested in three simple steps:
The 52-week high price of Apogee Therapeutics, Inc. Common Stock (APGE) is $72.29. The 52-week low price of Apogee Therapeutics, Inc. Common Stock (APGE) is $20.78.
The price-to-earnings (P/E) ratio of Apogee Therapeutics, Inc. Common Stock (APGE) is
The price-to-book (P/B) ratio of Apogee Therapeutics, Inc. Common Stock (APGE) is 3.87
The dividend yield of Apogee Therapeutics, Inc. Common Stock (APGE) is 0.00%
The market capitalization of Apogee Therapeutics, Inc. Common Stock (APGE) is $2.84B
The stock symbol (or ticker) of Apogee Therapeutics, Inc. Common Stock is APGE